FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Preoperative single-dose systemic steroid in major head and neck surgery (J-SUPPORT 2002, PreSte-HN Study): a phase III, placebo-controlled, randomized, double-blind study. PMID 42479256 · Int J Clin Oncol · 2026-Jul-21 The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it does not include a primary or key secondary time-to-event efficacy endpoint as defined (e.g., OS, PFS, DFS, HR, Kaplan-Meier), so it is ineligible. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial. PMID 42477619 · BMC Cancer · 2026-Jul-21 The study is a randomized, drug-intervention oncology trial with a time-to-event primary endpoint (PFS). However, it is explicitly described as an 'exploratory randomized trial' and its phase is not stated as Phase III/IIIb or Phase II/III in the abstract. The eligibility criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here. The study is also described as exploratory and of small sample size (n=68), further suggesting it is not a definitive trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. PMID 42511798 · Int J Mol Sci · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial. PMID 42476886 · Eur Urol · 2026-Jul-20 The report is from a Phase 3 randomized trial in oncology (prostate cancer) but focuses on patient-reported outcomes (quality-of-life/safety) after radiotherapy, which is a non-drug intervention. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or any Kaplan-Meier/HR analysis. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Strengthening awareness and community resources for early detection of lung cancer through navigation guided screening in American Indian/Alaska Native clinics (SACRED LUNGS): Study protocol. PMID 42476254 · Contemp Clin Trials · 2026-Jul-20 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis. PMID 42476253 · Contemp Clin Trials · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis. PMID 42475879 · EBioMedicine · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies. PMID 42474934 · J Gastrointest Cancer · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. PMID 42473802 · Future Oncol · 2026-Jul-20 The record describes a Phase III, randomized trial protocol for a novel monoclonal antibody in a rare soft tissue tumor. It is a human oncology study with a drug intervention. However, it is a protocol/registration summary without reported efficacy results, and no primary or secondary time-to-event endpoint (such as OS, PFS, DFS, or HR) is mentioned. Therefore, it does not meet the criteria for an original formal-result report of a completed trial. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. PMID 42473780 · Arthritis Rheumatol · 2026-Jul-20 The study is a Phase 3 randomized trial of a drug (deucravacitinib) with primary results, but it is for psoriatic arthritis (not a human malignant neoplasm) and its primary/secondary endpoints are response rates (ACR20, HAQ-DI, etc.), not time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC). PMID 42472751 · Ann Surg Oncol · 2026-Jul-20 The record describes a randomized oncology trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (OS). However, the explicit trial phase is not stated in the title, abstract, or metadata. Phase cannot be inferred from the study design or context. Therefore, eligibility is indeterminate. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data. PMID 42172567 · J Clin Oncol · 2026-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. PMID 42150145 · J Clin Oncol · 2026-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial. PMID 42497645 · Breast · 2026-Jul-19 The study is a phase III randomized controlled trial in oncology (breast cancer), but it compares surgical techniques (minimal incision-assisted endoscopic vs. conventional open breast-conserving surgery) and does not involve a drug-containing intervention. The primary and secondary endpoints are patient-reported outcomes (scar satisfaction, QoL) and surgical metrics, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. PMID 42472670 · Am J Hematol · 2026-Jul-19 The study is a randomized Phase III trial with a drug intervention (eltrombopag) and time-to-event endpoints (OS, DFS, EFS), but it is for severe aplastic anemia, a non-oncology hematologic disorder, not a malignant neoplasm. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117). PMID 42471483 · Br J Cancer · 2026-Jul-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment. PMID 42470850 · Cancer Treat Res Commun · 2026-Jul-18 The record describes an exploratory subgroup analysis within a larger randomized trial, not the primary results of a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Milk of magnesia in enhanced recovery after surgery for preventing postoperative ileus after hysterectomy: randomized controlled trial. PMID 42470487 · Support Care Cancer · 2026-Jul-18 The study is a randomized trial in an oncology population but does not meet key eligibility criteria: the intervention is not an anticancer drug (milk of magnesia), and the endpoints are not time-to-event oncology efficacy endpoints. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial. PMID 42470465 · Support Care Cancer · 2026-Jul-18 The record describes a randomized trial in oncology patients receiving chemotherapy, but the primary endpoint is fall incidence, not a time-to-event efficacy endpoint (like OS or PFS). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for a Kaplan-Meier digitization cohort focused on drug efficacy time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer. PMID 42464196 · BMC Cancer · 2026-Jul-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. PMID 42012456 · Clin Cancer Res · 2026-Jul-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial. PMID 42001507 · Clin Cancer Res · 2026-Jul-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies. PMID 41854411 · Clin Cancer Res · 2026-Jul-17 The record is a prospective, single-arm trial (n=43) of primary endocrine therapy (pET) with correlative ctDNA analysis. It is not a randomized trial, does not involve a drug-containing intervention arm compared to another arm, and is not Phase III or Phase II/III. Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted versus open pancreatoduodenectomy for cancer in the pancreatic head (DIPLOMA-2x2): study protocol for an international multicentre patient- and assessor-blinded randomized controlled non-inferiority trial. PMID 42464359 · Trials · 2026-Jul-16 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial. PMID 42463362 · Eur Urol · 2026-Jul-16 The record describes a Phase 3 randomized controlled trial in oncology (prostate cancer), but lacks an abstract and specific details. Key criteria (human subject, drug intervention, time-to-event endpoint, original result) cannot be established from the provided metadata. The title indicates a diagnostic imaging intervention ([68Ga]Ga-PSMA-11 PET-CT), which may not be a 'drug-containing intervention' as defined for this cohort, but this is uncertain. The primary endpoint is not specified as time-to-event (e.g., OS, PFS). Therefore, eligibility cannot be determined. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of silver diamine fluoride in preventing radiation-induced caries: A pilot study. PMID 42461172 · J Am Dent Assoc · 2026-Jul-16 The study is a randomized, placebo-controlled trial in oncology (prevention of radiation-induced caries in head and neck cancer patients). However, the intervention (silver diamine fluoride) is a topical preventive dental agent, not a drug-containing anticancer intervention. The primary endpoint is caries increment (a count/surfaces outcome), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. PMID 41789864 · N Engl J Med · 2026-Jul-16 未发现恶性肿瘤人群证据。 |
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis. PMID 42512335 · Cancers (Basel) · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences. PMID 42512331 · Cancers (Basel) · 2026-Jul-15 The record is a psychometric validation study of the PRO-CTCAE Average Composite Score. While it uses data from a Phase III randomized trial (COMET-2), the report's primary purpose is to evaluate the measurement properties of a patient-reported outcome instrument, not to present the trial's efficacy results (e.g., OS, PFS, HR). Therefore, it does not meet the criteria for an original formal-result report of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007). PMID 42458791 · J Natl Cancer Inst · 2026-Jul-15 This is an original report of a randomized trial (RxPONDER) with a drug intervention (endocrine therapy ± chemotherapy) and a time-to-event endpoint (IDFS). However, it is not a primary or key secondary result report for the overall trial efficacy. The analysis is a pre-specified subgroup/biomarker analysis focusing on gene expression components and disparities by ethnicity, not the primary trial outcome. The phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review. PMID 42458108 · Blood Res · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PMID 42457481 · Eur Urol Focus · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Advanced and Salvage Techniques for Difficult Biliary Cannulation in ERCP: A Randomized Trial of Outcomes and Efficacy. PMID 42456983 · Gastrointest Endosc · 2026-Jul-15 The record is not an oncology Kaplan-Meier digitization cohort eligible study. It is a randomized trial in gastroenterology evaluating procedural techniques, not a drug intervention for human malignant neoplasm with a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dose-escalated versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: 9-year Results of a Randomized Phase 2 Trial. PMID 42456783 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial. PMID 42456132 · JMIR Res Protoc · 2026-Jul-15 The record is a protocol for a randomized, placebo-controlled trial. While it meets criteria for oncology, human, randomized, drug intervention, and a time-to-event primary endpoint, it is explicitly a protocol without reported results. Furthermore, the trial phase is not specified as Phase III/IIIb or Phase II/III, which is a required eligibility criterion. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial. PMID 42455561 · JAMA Surg · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation. PMID 42428070 · medRxiv · 2026-Jul-15 The record is an observational cohort study using target trial emulation with propensity score matching, not a randomized Phase III trial. Although it involves oncology, human patients, drug interventions, and time-to-event endpoints (OS), the lack of randomization and confirmed Phase III/IIIb or Phase II/III status makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs. PMID 42325011 · Gut Liver · 2026-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity. PMID 41787605 · Int J Cancer · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies. PMID 41741956 · Int J Cancer · 2026-Jul-15 Study is a microsimulation modeling analysis comparing prostate cancer screening strategies; it is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention with a primary time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials. PMID 41663033 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Consolidation Chemotherapy After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: 7-Year Follow-Up Results of a Randomized Multicenter Trial (KCSG CO 14-03). PMID 41548612 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials. PMID 41419191 · Biol Psychiatry · 2026-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. PMID 42447419 · J Clin Oncol · 2026-Jul-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial. PMID 42446091 · Future Oncol · 2026-Jul-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms. PMID 42443407 · Leukemia · 2026-Jul-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. PMID 42441933 · J Clin Oncol · 2026-Jul-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life. PMID 42439956 · Cancer Chemother Pharmacol · 2026-Jul-13 While the trial is a randomized Phase III oncology study with a drug intervention and reports original results, the primary endpoint is safety, and the oncologic outcomes (recurrence, mortality) are exploratory and not analyzed or reported as formal time-to-event endpoints (e.g., no Kaplan-Meier estimates, hazard ratios, or mention of time-to-event statistics). Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial. PMID 42439484 · Circulation · 2026-Jul-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| An intervention for fear of progression in childhood cancer patients and their parents: feasibility and preliminary efficacy in a pilot randomised controlled trial. PMID 42437909 · BMC Pediatr · 2026-Jul-13 The record is a pilot RCT of a psychotherapeutic intervention in pediatric oncology. It is randomized and original, but it is excluded because it does not meet the drug intervention and time-to-event endpoint criteria required for inclusion. The phase is not explicitly stated but is likely early-phase (pilot), not definitively Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |